1832 Asset Management
SRPT icon

1832 Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

1832 Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-58,600
Closed -$7.59M – 968
2022
Q4 		$7.59M Sell
58,600
-17,100
-23% -$1.98M 0.01% 382
2022
Q3 		$8.37M Buy
+75,700
New +$7.63M 0.02% 379
2019
Q3 		– Sell
-17,500
Closed -$2.63M – 745
2019
Q2 		$2.63M Buy
+17,500
New +$2.13M 0.01% 381
2019
Q1 		– Sell
-14,700
Closed -$1.6M – 704
2018
Q4 		$1.6M Sell
14,700
-700
-5% -$87.5K 0.01% 371
2018
Q3 		$2.49M Buy
+15,400
New +$2.11M 0.01% 358

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

1832 Asset Management's SRPT Position: Q1 2023 in Review

1832 Asset Management sold out of Sarepta Therapeutics (SRPT) in Q1 2023, closing a stake of 58,600 shares — an estimated $7.59M sold.

1832 Asset Management first reported a position in SRPT in Q3 2018 and held it in 5 quarters. The position peaked at $8.37M in Q3 2022. 425 funds tracked by Wall St. Rank hold SRPT as of Q1 2023.

  • 1832 Asset Management reported no remaining Sarepta Therapeutics position as of Q1 2023 after selling out during the quarter.
  • 1832 Asset Management sold 58,600 Sarepta Therapeutics shares in Q1 2023, an estimated $7.59M.
  • 1832 Asset Management first reported a position in Sarepta Therapeutics in Q3 2018 and held it in 5 quarters.
  • 1832 Asset Management's Sarepta Therapeutics position peaked at $8.37M in Q3 2022.
  • 425 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2023.

Based on 1832 Asset Management's 13F filing for Q1 2023, filed 12 May 2023.